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Dr Richard Lee (St Louis, Mo). I have no disclosures. Dr Ad,
this is an important contribution to the field. I have 2 questions that
I will ask 1 at a time.
First, the freedom from AF that you reported was an impressive
95%, which has been duplicated in some other single institution
series. However, in the Concomitant Utilization of Radio Fre-
quency Energy for Atrial Fibrillation trial and ABLATE-AF trial,
the freedom from atrial fibrillation was 67% and 84%, respec-
tively, using the same lesion set as in your series at multiple centers
and with multiple surgeons. How do you account for the superior-
ity of your results and does this limit the generalizability of your
prediction model to other centers?
Dr Ad.Well, Rick, thank you. There are many ways to answer
this question. One of the only smart decisions I made regarding
the surgical treatment of AF was basically to take what I learned
in the past very seriously; I never changed it. Dr Jim Cox pre-
sented his concept>25 years ago, and I actually never moved
away from it.
I believe that the only difference between our group and others
is that we all perform the correct Maze lesion set using only tools
with proven transmurality; these are not only my own results. I
think if you do this, your success rate is going to be high.
Dr Lee. Second, in your report, you were kind enough to cite
one of my studies that showed a survival advantage for patients
surgically treated for AF. However, in that population, only those
patients whowere free from both AF and antiarrhythmic therapy at
1 year had improved survival, similar to the implications of the
multivariable analysis of the Atrial Fibrillation Follow-up Investi-
gation of Rhythm Management trial.
Please clarify why you did not use freedom from AF and anti-
arrhythmic agents as a primary endpoint and what needs to
be done to establish a prediction model for this important
variable?
Dr Ad.Well, that is an interesting question. Again, this is a first
step, and I think it is an important step, where we can sit and talk
with the patient and say, you know, this is the prediction of you be-
ing in SR.Whether SR without and with medication is the key, this
is still an open question, and, despite the guidelines, some of us
strongly disagree with this type of definition. However, being
clearer, the model is still as accurate when you take the medication
variable out, we just did not believe it was important to include
here to avoid confusion. I think in the future when we have more
collaboration and more patients, we will be able to also predict
freedom from cardioversion and freedom from antiarrhythmic
drugs.ery c September 2014
Ad and Holmes Acquired Cardiovascular Disease
A
C
DMind you, we were persistent in the adherence to the HRS
guidelines, such that any ablation was considered a failure.
Dr Vinay Badhwar (Pittsburgh, Pa). Niv, another wonderful
contribution, and I think what is extremely important is that all
our current scoring systems of the quality of cardiac surgery are
currently focused on major morbidity and mortality outcomes,
and this is one of the first that will be focusing on a no mortality
and no morbidity procedural efficacy outcome.
I know from your past work that your lesion set has been consis-
tent, as has been its energy source. As a part of your predictive
model, just for clarification of us all, was this consistent
throughout all patients and all surgeons performing the same
lesion set with the same ‘‘tool,’’ as you called it?
Dr Ad. I am not operating all the time, but the group, in general,
I think is fairly educated about the lesion sets and how to apply
them, and I believe that this is the key. Also, the energy sources be-
ing used were either cryothermia alone or a combination of bipolar
radiofrequency and cryothermia, which previous publications,
ours and others, showed no difference between them.
Dr Badhwar. On the basis of that answer, perhaps it would be
wise to include the energy source and precise lesion set adherence
before external validation. Do you think this would be a factor in
the development of a scoring system?
Dr Ad. I think that it might be a good idea. I question whether it
is going to add anything, because I predict that, at least in our
model, it will not show any significance at 1 or 2 years whether
you use bipolar and cryothermia or cryothermia alone, and Ralph
is here and can comment on that. I think it is an excellent question.
I just do not believe that, at least in our center, it will show any
difference.
As for a lesion set, this is specifically a Cox maze III or IV, it
depends on how you want to call it, lesion set in all patients, and
that is crucial. I can go back and look, because, as you know, in
our database it has been entered after every case whether there
were deviations from the Cox maze procedure perceived by the
surgeon, and, again, if so, it occurred in very few patients.
Dr A. Peter Kappetein (Rotterdam, The Netherlands). It is
great, as Dr Badhwar pointed out, that you have developed an ef-
ficacy model instead of just a safety model. The AUC of 0.85 is
impressive and very difficult to achieve in any other prediction
model. You only had 525 patients to develop this model, and
your success rate was pretty high for achieving SR.
So how many endpoints did you have? In other words, how
many patients had AF during follow-up? Because these are the
ones for which you want to try to find the predictive factors.
That is a relatively small proportion.
In your abstract, you stated that a 1-cm increase in LA size re-
sulted in a 2.3% reduction in the success rate. That means that if
you have a success rate of 98%, it will decrease to 95.7%. How
can it be so accurate, and do you assume that all variables have
a linear relationship with the outcome? Because I can also imagine
that if the LA size is greater than a certain threshold, treatment will
not be so successful.
Dr Ad. I think that it is something we were surprised at. This
obviously I consider one of our most important projects ever. I
was fairly surprised, and we did check ourselves again and again
and again, and these are indeed the data, and whoever knows usThe Journal of Thoracic and Caknows that this is really something we take a lot of pride in, our
reliability in reporting results.
The LA size might be a little different in the prediction for fail-
ure compared with other centers, because more experienced sur-
geons were managing a larger atrial size. Also, we published a
couple of months ago that 2 sizes are crucial in which we should
pay attention for success, whether with or without medication,
5.5 cm and 7.5 cm. However, even if you treat patients with
a>10-cm left atrium, the success rate without medication at 2
years was>50%, but there are not many.
Dr Kappetein. So you assume still that you can use it as a
continuous variable instead of as a categorical variable?
Dr Ad. Yes.
DrKappetein.Howmany patients actually did not achieve SR?
In how many patients was treatment not successful?
Dr Ad. I do not remember off the top of my head, but, again, we
classified failures in a few categories that can correlate with
burden: 30 seconds to 5 minutes, 5 minutes to 1 hour,>1 hour,
and continuous. But I do not remember it off the top of my head.
Dr Kappetein. Because that is a very important figure.
Dr Ad. Good point.
Dr Sary F. Aranki (Boston, Mass). I have a question regarding
anticoagulation. How do you use your prediction model in manag-
ing anticoagulation in those patients and does the size of the left
atrium have any effect on your management decision?
Dr Ad. First, the prediction model is not designed to answer
whether the patient will require anticoagulation. What we do prac-
tically for anticoagulation is basically 3 months of postoperative
antiarrhythmic drugs and anticoagulation, then we stop the antiar-
rhythmic drugs, and we monitor the patient—long-term moni-
toring, anywhere from 4.5 months to 6 months. When we see
that they are basically not in AF based on this type of assessment
and the echocardiogram shows that no smoke is present in the
atrium and the LA appendage has been controlled, the recommen-
dation to stop anticoagulation applies.
If smoke is present in the left atrium or the LA appendage is not
well controlled and the patient has higher CHADS scores, we have
some discussions around all of it. Our rate of stopping anticoagu-
lation has been fairly high. One caveat is that in many cases it will
be the decision of the cardiologist, and, despite our recommenda-
tion, the patient will continue with anticoagulation medication.
However, theoretically, if you remove all the patients who do not
require anticoagulation due to AF or other reasons, such as a
mechanical valve or deep venous thrombosis, you can basically
eliminate warfarin in>85% of the patients after 6 months.
Dr Harold L. Lazar (Boston, Mass). I just have 1 final ques-
tion. Using your scoring system, are there any patients for whom
you would not perform a concomitant maze procedure because
you think that it just would not work?
Dr Ad. No, for myself; however, in the group, I think it varies.
We have shown in the past, in work that was published in the
Annals, that attrition occurs in the implementation of the Cox
maze procedure for patients with more risk factors and, especially,
with a larger left atrium and long AF duration. However, person-
ally, I think you can achieve much greater than a 50% success
rate over time in extremely complex cases if you do it in an appro-
priate way, so it is worth it.rdiovascular Surgery c Volume 148, Number 3 887
